Case study

Pricing and indication assessment for SIBO (small intestinal bacterial overgrowth) under Pediatric use Marketing Authorization (PUMA) regulations

Client Situation

Our client distributes a portfolio of prescription products for patients suffering from GI, metabolic and neurological disorders. Their goal was to understand the pricing, reimbursement landscape, and potential challenges for their product seeking approval under the PUMA regulation in the EU4+UK. Additionally, they sought to explore physicians’ willingness to use their product for SIBO

flag_image

Project Scope

    To assess the perception of SIBO indication and pricing potential for a product approved under PUMA regulation in EU4 + UK

Focus Markets

flag_image

Solutions

    We conducted extensive primary research to get detailed insights on:

  • Feasibility of achieving PUMA for SIBO
  • Payer attitude towards the SIBO indication and perceived value of the test product
  • Impact of PUMA on overall pricing and reimbursement potential
  • Likelihood of achieving price premium in EU4+UK
flag_image

Results

  • Clear overview, for the client, of product adoption considerations, including acceptable price points from payers' perspective and factors influencing SIBO acceptance among payers